TABLE 2.

Distribution of HPV and cytology results of the CDC’s NBCCEDP cohort from 2009 to 2017

Test results		N	%	CIN2+	CIN3+	Cancer	Follow-up time, mo		% with colposcopy or follow-up
HPV	Cytology						Median	IQR
Screened in the past 5 y
Total		208,656	100.0	2873	1495	236	25	14–42
HPV Positive	NILM	11,315	5.4	196	115	7	16	13–27	31
	ASC-US	11,754	5.6	1215	545	22	18	13–33	87
	LSIL	3728	1.8	410	159	6	18	13–30	85
	ASC-H	567	0.3	200	138	10	16	12–27	92
	AGC	244	0.1	92	69	15	17	14–29	91
	HSIL+	747	0.4	486	337	37	15	12–26	89
HPV Negative	NILM	152,606	73.1	44	19	4	34	17–50
	ASC-US	25,186	12.1	104	45	7	26	14–46
	LSIL	1461	0.7	31	11	0	15	13–26	57
	ASC-H	293	0.1	29	14	0	17	14–31	90
	AGC	669	0.3	33	19	12	21.5	14–38	91
	HSIL+	86	0.0	33	24	3	11	8–17	87
Rarely or never screened
Total		113,126	100.0	1827	1124	165	22	14–38
HPV Positive	NILM	6554	5.8	112	68	11	15	13–25	23
	ASC-US	5130	4.5	636	315	30	16	13–29	84
	LSIL	1862	1.7	215	87	1	16	13–27	81
	ASC-H	293	0.3	121	88	15	14	10–19	85
	AGC	175	0.2	80	67	20	16	10–32	85
	HSIL+	667	0.6	504	402	58	17	13–27	91
HPV Negative	NILM	87,187	77.1	19	13	6	29	16–43.25
	ASC-US	9926	8.8	31	10	2	27	14–45
	LSIL	701	0.6	14	3	0	15	13–23	51
	ASC-H	160	0.1	16	7	2	16.5	13–33.25	86
	AGC	386	0.3	31	25	17	15	13–25.75	85
	HSIL+	85	0.1	48	39	3	14	10–26	89
Unknown screening history
Total		41,762	100.0	721	414	71	28	15-47
HPV Positive	NILM	2565	6.1	42	21	4	15	13–27	24
	ASC-US	2090	5.0	276	126	15	19	13–30	83
	LSIL	838	2.0	109	59	9	17	13–28	77
	ASC-H	123	0.3	40	23	3	34	19.75–39	79
	AGC	76	0.2	28	22	7	31	13.5–49.75	87
	HSIL+	251	0.6	183	136	22	22	14–36	89
HPV Negative	NILM	32,069	76.8	2	2	1	37	21–58
	ASC-US	3270	7.8	9	5	2	27	14–47
	LSIL	293	0.7	9	3	2	15	13-19.5	52
	ASC-H	43	0.1	1	1	0	16	13–6	79
	AGC	117	0.3	7	5	5	17	13–25	84
	HSIL+	27	0.1	15	11	1	13.5	13–20.75	85

AGC, atypical glandular cell; ASC-H, atypical squamous cells-cannot exclude HSIL; ASC-US, atypical squamous cells of uncertain significance; CDC, Centers for Disease Control and Prevention; CIN2+, cervical intraepiethial neoplasia grade II or greater; CIN3, cervical intraepiethial neoplasia grade III or greater; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; IQR, interquartile range; LSIL, low-grade squamous intraepithelial lesion; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; NILM, negative for intraepithelial lesion or malignancy.